Omeros Corporation (OMER)

NASDAQ: OMER · IEX Real-Time Price · USD
3.450
+0.030 (0.88%)
At close: Mar 28, 2024, 4:00 PM
3.400
-0.050 (-1.45%)
After-hours: Mar 28, 2024, 4:44 PM EDT

Company Description

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders.

The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction.

In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders.

Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Omeros Corporation
Omeros logo
Country United States
IPO Date Oct 8, 2009
Industry Biotechnology
Sector Healthcare
Employees 196
CEO Dr. Gregory A. Demopulos M.D.

Contact Details

Address:
201 Elliott Avenue West
Seattle, Washington 98119
United States
Phone 206-676-5000
Website omeros.com

Stock Details

Ticker Symbol OMER
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001285819
CUSIP Number 682143102
ISIN Number US6821431029
Employer ID 91-1663741
SIC Code 2834

Key Executives

Name Position
Dr. Gregory A. Demopulos M.D. Co-Founder, Chairman, Chief Executive Officer and President
Michael A. Jacobsen Chief Accounting Officer, Vice President of Finance and Treasurer
Peter B. Cancelmo J.D. Vice President, General Counsel and Corporate Secretary
Dr. Pamela Pierce Palmer M.D., Ph.D. Co-Founder
Dr. George A. Gaitanaris M.D., Ph.D. Chief Scientific Officer and Vice President of Science
Peter W. Williams Vice President of Human Resources
Dr. Catherine A. Melfi Ph.D. Chief Regulatory Officer and Vice President of Regulatory Affairs and Quality Systems
Nadia Dac Vice President and Chief Commercial Officer
Dr. Andreas Grauer M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 27, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 8-K Current Report
Jan 29, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 9, 2023 10-Q Quarterly Report
Nov 9, 2023 8-K Current Report
Oct 16, 2023 8-K Current Report
Sep 20, 2023 144 Filing
Aug 9, 2023 S-8 Securities to be offered to employees in employee benefit plans